PubMed Health⌕ Search

Biomedical subjects

S Fu

Publications and source records attributed to S Fu.

At least 127 records · Page 7Linked to original sources
PubMed1988

Clinical use of praziquantel in China.

Praziquantel, a broad-spectrum anthelmintic developed by E. Merck and Bayer AG in Germany in the early 1970s, was synthesized in the People's Republic of China in 1977 and given the Chinese name Pyquiton. After a series of pharmacological and toxicological studies in China, praziquantel was released for clinical use in 1978. The drug is now available for treatment of human schistosome and other trematode infections as well as the treatment of cestode infections including cysticercosis. However, much of the clinical work has been published in Chinese journals that may not be universally familiar. This article summarizes some of the key aspects of these reports, dealing with the clinical use of praziquantel against schistosomiasis japonica and other helminth infections in China.

Journal Article↗
PubMed1987

In situ hybridization and immunocytochemistry for improved assessment of human immunodeficiency virus cultures.

The authors characterized the early intracellular events involved in human immunodeficiency virus (HIV) replication after in vitro inoculation into cultures of susceptible human T-cell lines and phytohemagglutinin-stimulated peripheral-blood mononuclear cells (PMCs). Within 24 hours of infection, in situ hybridization with HIV DNA probe detected cytoplasmic viral RNA. Viral core antigen was detected in infected cells over the subsequent two to ten days by means of an immunocytochemical assay employing monoclonal antibodies. Several days later, cell-free virus was detected by both reverse transcriptase assay and a p25gag antigen-capture assay. When these methods were applied to monitor cultures of ten sero-positive persons' PMCs, a similar progression of virus replication was apparent: cytoplasmic viral RNA was detected in infected PMCs by day 3, with the subsequent appearance of intracellular viral proteins (days 6-9) and cell-free virus (days 12-21). In situ hybridization and immunocytochemistry offer complementary, sensitive, and specific approaches for monitoring the early stages of acquired immune deficiency syndrome virus replication in vitro.

Acquired Immunodeficiency Syndrome↗
PubMed1986

In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum.

A 48 h in vitro test was conducted to compare the susceptibility of two strains of Plasmodium falciparum to chloroquine, the two enantiomers of chloroquine, desethylchloroquine and the new antimalarial drug pyronaridine. The five compounds similarly inhibited the chloroquine sensitive strain. However, desethylchloroquine was less active and pyronaridine was much more active than chloroquine and its enantiomers against the chloroquine resistant strain.

Antimalarials↗
PubMed1984

Clinical trial on furapyrimidone in filariasis.

A clinical trial was carried out with furapyrimidone in treating 51 patients with B. malayi, 159 with W. bancrofti and eight with D. perstans using different dosage schedules. Two hundred and fifty-seven cases of Malayan and bancroftian filariasis were treated with hetrazan for comparison. The results based on the microfilaricidal effects suggest that furapyrimidone possesses similar therapeutic effects of hetrazan on Malayan filariasis at eight-month follow-up, and higher incidences of microfilarial disappearance of W. bancrofti infection (81.3%) at six-month follow-up. The drug was also effective against D. perstans. The side effects consisted of fever and irritation of the digestive tract. Fever may be related to allergic reaction of foreign protein from the dead or dying parasites. The side reactions are similar to those of hetrazan and usually not serious. Comparing the efficacies and side effects of furapyrimidone with different dosage schedules the authors recommend regimens of 15 to 20 mg/kg/day for six days in treating Malayan filariasis and 20 mg/kg/day for seven days in treating bancroftian filariasis.

Adolescent↗
PubMed1983

A retrospective survey on side effects of praziquantel among 25,693 cases of schistosomiasis japonica.

A retrospective survey involving 25,693 persons was carried out in four provinces and the city of Shanghai, China between December 1981 until May 1982 to document relatively serious side effects of praziquantel used in a mass treatment programme for schistosomiasis japonica. Only 122 or 0.47% of those participating in the study had experienced relatively serious side reactions to the drug. Most had only one kind of side effects but two or more were recorded in a few patients. Neuropsychiatric reactions were seen in 39 persons (0.15%,) cardiovascular reactions in 37 (0.14%), hepatic changes in four (0.02%), dermatological reactions in 18 (0.07%) and delayed reactions resulting in fatigue and inability to work in 29 (0.11%). Praziquantel remains the drug of choice for the treatment of oriental schistosomiasis, it is highly effective and although side effects are minimal, caution should be taken in the treatment of chronic disease with heart failure, ascites, poor hepatic compensation and renal failure.

Adolescent↗
PubMed1974

Immunoglobulin synthesis in vitro by lymphocytes from patients with immune deficiency: requirements for a special serum factor.

Certain patients with immune deficiency were encountered whose peripheral blood lymphocytes included no immunoglobulin-bearing cells. However, other markers of B type lymphocytes were observed; lymphocytes isolated free of macrophages showed the presence of receptors for the Fc fragment of IgG and for the third component of complement. One patient with a syndrome of thymoma and severe hypogammaglobulinemia was studied in special detail. In vitro the patient's cells were able to develop surface Ig in media supplemented with fetal-calf serum or normal human serum; in media supplemented with autologous serum, the cells developed no surface Ig. During culturing antigenic determinants of immunoglobulin became detectable in the medium, and both medium and cell-surface immunoglobulin underwent a shift from specific IgM determinants early in the culture period to IgG and IgA determinants later. Normal lymphocytes and thymocytes activated by concanavalin A repaired the deficiency in the patient's serum. These data support the concept that a factor possibly derived from T cells is missing from this patient's serum and that this factor is required for the maturation of the B cell for immunoglobulin synthesis.A patient with X-linked agammaglobulinemia had a population of circulating lymphocytes with some surface characteristics that appeared similar to those of the B cells from the patient with thymoma. In contrast, however, no Ig synthesis by this patient's cultured cells could be demonstrated. The possible nature of the lymphocytes reacting with aggregated IgG in this case is discussed.

Adult↗